Thompson AJ, Muir AJ, Sulkowski MS, et al: InterleukinB polymorphism improves viral kinetics and is the strongestpretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Download references. You can also search for this author in PubMed Google Scholar. Correspondence to Adriano M Pellicelli. All the authors declares the they not have received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future.
All the authors declares that they do not hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future. All the authors declare that they do not hold or apply any patents relating to the content of the manuscript. All the authors declare that they have not received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript.
All the Authors declare that they not have any other financial competing interests. LN Data acquisition, literature search. FM Data acquisition, manuscript review.
CP Data acquisition, manuscript preparation, analysis of laboratory data. GB Statistical analysis ,Manuscript review. RM Data acquisition and manuscript review. EM Manuscript editing, Data acquisition. AP Data acquisition. MEB Manuscript review, data acquisition. CM Data acquisition. PV statistical analysis, data acquisition, manuscript editing.
AA Manuscript editing, literature search. MM Literature search, data acquisition. CD Manuscript preparation, Data acquisition, Concept. LM Manuscript review, Data acquisition. OM Laboratory analysis, Data acquisition. UVG data acquisition. Manuscript preparation. All the authors read and approved the final manuscript.
This article is published under license to BioMed Central Ltd. Reprints and Permissions. Pellicelli, A. BMC Gastroenterol 12, Download citation. Received : 18 June Accepted : 13 November Published : 16 November Anyone you share the following link with will be able to read this content:.
Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative.
Skip to main content. Search all BMC articles Search. Download PDF. Abstract Background The impact of viral subtype on the rate of sustained virological response SVR to antiviral therapy in patients chronically infected with hepatitis C genotype 1 subtype 1a and 1b has not been extensively investigated. Conclusion Dual antiviral therapy is more effective against HCV subtype 1a than against subtype 1b and this difference is independent of other factors that may favour viral clearance.
Trial registration ClinicalTrials. Background Despite the promise of new antiviral drugs that can act directly on hepatitis C viral replication such as protease and polymerase inhibitors, a 48 weeks course of PEGylated interferon PEG-INF combined with ribavirin remains the current standard treatment for genotype 1 chronic hepatitis C CHC [ 1 , 2 ].
Statistical analysis All analysis were performed on the basis of the intention to treat ITT ;i. There are also subtypes labeled with letters, for example, genotypes 1a and 1b. Most people are infected by a single, dominant genotype, but it is possible to have more than one at the same time called a mixed infection. Knowing your HCV genotype is important information that can help patients and doctors find the most effective treatment. All HCV genotypes cause the same amount of liver damage.
However, people infected with genotype 1, particularly subtype 1b, may have a greater chance of developing cirrhosis , or severe liver scarring, than other genotypes. Genotypes 1b and 3 may increase the risk of liver cancer. HCV can now be cured by all oral, direct-acting antivirals DAAs , medications that prevent the hepatitis C virus from make copies of itself. This allows your immune system to clear the virus out of your body.
How well a DAA works depends on where it sticks to the target proteins in the virus. Some of the latest DAA treatments are pangenotypic , which means they can cure all genotypes at nearly the same rates. A person of any racial or ethnic group can carry any genotype or subtype. These changes could affect the process of anchoring this protein in the ER and might contribute to the reduced efficiency of viral replication, favouring the control of viremia and the action of IFN or RBV.
Studies based on mutations in the CRS region are almost nonexistent and more mutation analyses in these regions are necessary. However, other studies have shown a significant association between treatment effectiveness and a high number of mutations within V3, with a significant difference between SVR and NR patients Murphy et al. The total number of aa variations observed in NS5A of HCV genotype 3a isolates from our study was not associated with treatment response.
However, the lack of significant differences between the groups could be due to the small sample size. Further studies on a larger number of patients are desirable to confirm or refute this finding.
However, more studies are needed to clarify its effects on other aspects of immunity. With the recent development of an HCV infection model such as the subgenomic HCV replicon cell culture system , future work will most certainly be aimed at investigating the role of NS5A in other aspects of the HCV life cycle, including viral entry and assembly.
As new in vivo models evolve, the role of NS5A in viral replication in animal models will certainly be defined. Thus, future research should provide new clues as to the various functions of this truly remarkable multifunctional regulatory protein. Abrir menu Brasil. Abrir menu. Key words: E2 protein - hepatitis C virus - interferon sensitivity determining region - NS5A protein - PKR-eIF2a phosphorylation homology domain Hepatitis C virus HCV is a member of the Flaviviridae family which usually causes chronic infection and can result in chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem : Bedossa P, Poynard T An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24 : Hepatology 32 : An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A.
Variability of the nonstructural 5A protein of hepatitis C virus type 3a isolates and relation to interferon sensitivity. J Infect Dis : Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. The amino acid sequence of the PKR-eIF2alpha phosphorylation homology domain of hepatitis C virus envelope 2 protein and response to interferon-alpha.
Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 79 : Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b.
Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96 : Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.
N Engl J Med : Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J Virol 74 : Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 18 : Evasion of intracellular host defence by hepatitis C virus. Nature : Clin Diagn Virol 10 : Gastroenterology : The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India.
Med Microbiol Immunol : Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. J Clin Virol 32 :
0コメント